Essential Hypertension Clinical Trial
Official title:
Effects of Remote Ischemic Conditioning on Blood Pressure in Older Patients With Hypertension
NCT number | NCT05845905 |
Other study ID # | RICBP-HT |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 10, 2023 |
Est. completion date | April 20, 2024 |
The purpose of this study is to learn about effects of remote ischemic conditioning on blood pressure in older patients with essential hypertension.
Status | Recruiting |
Enrollment | 158 |
Est. completion date | April 20, 2024 |
Est. primary completion date | April 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years to 85 Years |
Eligibility | Inclusion Criteria: - 1) Age =65 years and =85 years, regardless of gender; - 2) History of essential hypertension and clinical systolic blood pressure = 140 mmHg, regardless of whether they are receiving antihypertensive medication; - 3) Willing to participate and sign the informed consent. Exclusion Criteria: - 1) Secondary hypertension; - 2) Clinical blood pressure = 180/110 mmHg or 24-hour mean arterial pressure = 170/100 mmHg; - 3) Severe organ dysfunction or failure; - 4) Severe hematologic disorders or significant coagulation abnormalities; - 5) History of atrial fibrillation or myocardial infarction within 6 months; - 6) Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; - 7) Individuals who will or have received anticoagulant therapy with drugs such as dabigatran, rivaroxaban, warfarin, etc; - 8) Those who are participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to enrollment; - 9) Other conditions that the researchers think are not suitable for the project. |
Country | Name | City | State |
---|---|---|---|
China | First Hospital of Jilin University | Changchun | Jilin |
Lead Sponsor | Collaborator |
---|---|
Yi Yang |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean systolic blood pressure | Difference in mean value of systolic blood pressure during RIC/sham-RIC between two groups. | 0-7 days | |
Secondary | Mean diastolic blood pressure | Difference in mean value of diastolic blood pressure during RIC/sham-RIC between two groups. | 0-7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03708601 -
Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
|
||
Not yet recruiting |
NCT05503953 -
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
|
Phase 3 | |
Recruiting |
NCT05526703 -
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
|
Phase 3 | |
Completed |
NCT06395194 -
Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension
|
Phase 3 | |
Not yet recruiting |
NCT06418074 -
Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity
|
N/A | |
Completed |
NCT02890173 -
Study of CS-3150 in Patients With Essential Hypertension
|
Phase 3 | |
Completed |
NCT02944734 -
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
|
Phase 2 | |
Withdrawn |
NCT02096939 -
Microvascular Function in Primary Aldosteronism
|
N/A | |
Recruiting |
NCT01956786 -
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
|
Phase 2/Phase 3 | |
Completed |
NCT02553512 -
Helius in Hypertension-I: The UK Hypertension Registry
|
N/A | |
Completed |
NCT01198249 -
Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension
|
Phase 1 | |
Completed |
NCT01001572 -
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
|
Phase 3 | |
Recruiting |
NCT00380289 -
Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
|
N/A | |
Completed |
NCT00139698 -
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
|
Phase 3 | |
Completed |
NCT00288184 -
Uric Acid in Essential Hypertension in Children
|
Phase 2 | |
Completed |
NCT01289886 -
Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06041529 -
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
|
Phase 4 | |
Completed |
NCT04470830 -
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
|
||
Completed |
NCT00758524 -
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
|
Phase 2 | |
Recruiting |
NCT05109013 -
Juvenile Essential Arterial Hypertension and Vascular Function
|